Effects of atorvastatin on higher functions
- First Online:
- 295 Downloads
This study was undertaken to assess the effects of atorvastatin on cognition and higher mental functions.
In this before and after comparison study with controls, group one included 55 subjects aged ≥40 years requiring statins for cardiovascular indications who were started on atorvastatin (10 mg/day). Group two assigned to receive placebo were men and women chosen from the same geographical area and matched for age, sex, education and presence of hypertension and diabetes mellitus. Assessment was done with the Mini-Mental State Examination, Digit Span, Picture Test (average and delayed), Trail Making Test, Controlled Oral Word Association Test, Digit Symbol Substitution Test and Auditory Vigilance and Digit Vigilance Test at baseline and after 6 months. Changes between baseline and 6 months in the above parameters of mental function were compared using suitable statistical tests in the atorvastatin and placebo groups. To limit experiment-wise error, performance scores were grouped into five cognitive domains, which were labeled as attention, psychomotor speed, mental flexibility, working memory and memory retrieval. Summary effect sizes were estimated as z-scores.
Both subjects on atorvastatin and placebo showed improvement in the majority of scales consistent with a learning effect on test performance. However, subjects treated with atorvastatin scored significantly over the placebo group in all domains, i.e. tests of attention [z-score=0.54, 95% confidence interval (CI): 0.38–0.64, p=0.001], psychomotor speed (z-score=0.28, 95% CI: O.09–0.47, p<0.001), mental flexibility (z-score=0.27, 95% CI: 0.22–0.32, p=0.01), working memory (z-score=1.22, 95% CI: 0.93–1.50, p<0.001) and memory retrieval (z-score=0.59, 95% CI: 0.36–0.82, p<0.05).
The present study concludes that there are significant beneficial effects of atorvastatin in a dose of 10 mg/day for a period of 6 months on higher functions as measured by the above standard neurocognitive tests.
KeywordsStatins Neurocognitive tests Atorvastatin Memory MMSE
- 6.Dales MJM (2000) Statination. Intern Med News 1:55–56Google Scholar
- 8.England JD, Viles A, Walsh JC, Stewart PM (1999) Muscle side effects associated with simvastatin therapy. Med J Aust 153:562–563Google Scholar
- 21.Laufs U, Bohm M, Gertz K et al (2002) The hydrophilic HMG-CoA reductase inhibitor rosuvastatin regulates endothelial NO synthase and ischaemic stroke in vivo. Circulation 106(19 suppl):I272Google Scholar
- 22.Lewis RF, Rennick PM (1979) Manual for repeatable cognitive perceptual motor battery. Axon, Clinton, MIGoogle Scholar
- 25.Muldoon MF, Flory JD, Ryan CM (2000) Serum cholesterol, the brain and cognitive functioning. In: Waldstein SR, Elias MF (eds) Neuropsychology of cardiovascular disease. Lawrence Erlbaum Associates, Mahwah, NJGoogle Scholar
- 29.Reitan RM, Wolfson D (1993) The Halstead-Reitan neuropsychological test battery. Theory and clinical interpretation, 2nd edn. Neuropsychological Press, Tucson AZGoogle Scholar
- 31.Rose GA, Blackburn H, Gillum RF, Prineas RJ (1982) Cardiovascular survey methods, 2nd edn. (WHO Monograph Series no. 56 vol 1) WHO, GenevaGoogle Scholar
- 36.Sparks DL, Connor DJ, Browne PJ et al (2002) HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer’s disease and why it would be ill-advised to use one that crosses the blood-brain barrier. J Nutr Health Aging 6:323–324Google Scholar
- 37.Spreen O, Strauss E (1991) A compendium of neuropsychological tests. Administration, norms, and commentary. Oxford University Press, New YorkGoogle Scholar
- 40.Wechsler D (1997) Wechsler Adult Intelligence Scale, 3rd edn. Psychological Corporation, San Antonio, TXGoogle Scholar
- 41.Wehr H, Parnowski T, Puzynski S et al (1996) Apolipoprotein E genotype and lipid and lipoprotein levels in dementia. Age Ageing 15:267–270Google Scholar